Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

Published:2016-03-11 Issue:5 Volume:71 Page:429-435
ISSN:0040-6376
Container-title:Thorax
language:en
Short-container-title:Thorax

Author:

Nathan Steven D,Albera Carlo,Bradford Williamson Z,Costabel Ulrich,du Bois Roland M,Fagan Elizabeth A,Fishman Robert S,Glaspole Ian,Glassberg Marilyn K,Glasscock Kenneth F^ORCID,King Talmadge E,Lancaster Lisa,Lederer David J,Lin Zhengning,Pereira Carlos A,Swigris Jeffrey J,Valeyre Dominique,Noble Paul W,Wells Athol U

Publisher

BMJ

Subject

Pulmonary and Respiratory Medicine

Reference17 articles.

1. An Official ATS/ERS/JRS/ALAT Statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management;Raghu;Am J Respir Crit Care Med,2011

2. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials;Noble;Lancet,2011

3. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis;King;N Engl J Med,2014

4. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis;Richeldi;N Engl J Med,2014

5. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference;du Bois;Am J Respir Crit Care Med,2011

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis;JCI Insight;2024-07-16

2. U-net convolutional neural network applied to progressive fibrotic interstitial lung disease: Is progression at CT scan associated with a clinical outcome?;Respiratory Medicine and Research;2024-06

3. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial;American Journal of Respiratory and Critical Care Medicine;2024-05-01

4. Comparative Pharmacokinetics and Safety Assessment of 1st‐ and 2nd‐Generation Zinpentraxin Alfa Drug Products in Healthy Volunteers: A Randomized Crossover Study;Clinical Pharmacology in Drug Development;2024-04-23

5. Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases;Heliyon;2024-04